Momenta's market cap currently stands at $414 mil which isn't exactly chump change.
Really? Based on what? A market cap is all relative to potential sales and earnings and the timing and likelihood of those sales and earnings in my book. A $100 million market cap can be expensive while a $400 million market cap can be cheap, depending on the opportunity for the company.
I would argue that the $400 million market cap for MNTA is actually pretty darned cheap given the significant market opportunity for just a generic Lovenox (i.e., ignoring the rest of the pipeline). What matters is of course whether the FDA grants approval, whether MNTA gets sole approval for a generic Lovenox, and the timing of that approval. I'm in the camp that believes a $400 million market cap for MNTA will look quite cheap in hindsight if those 3 matters go in MNTA's favor. And I still think the stock will be a good deal higher even if multiple generics are approved as we would still be looking at significant revenues for MNTA in the very near future.
Market Data 
Markets 
AI
